Table 1

Demographic and clinical status of patients with anti-NMDAR encephalitis

Anti-NMDAR encephalitis (n=61)
Age (years, mean±SD)25.6±15.6
Age (years, n, %)
 4–1723 (37.7)
 18–4428 (45.9)
 45–6410 (16.4)
Gender (female, n, %)31 (50.8)
BMI (median, range)20.4 (8.3–30.4)
Season
 Spring:summer:fall:winter23:14:10:14
mRS before treatment (median, range)4.0 (1.0–5.0)
mRS after the treatment* (median, range)2.0 (0.0–5.0)
CSF anti-NMDAR Abs positive (n, %)61 (100)
CSF pleocytosis (n, %)36 (59.1)
CSF protein increase (n, %)14 (23.0)
CSF virus-Abs positive (n, %)7 (11.5)
 HSV-1 IgG2 (3.3)
 HSV-1/2 IgG4 (6.6)
 CMV-IgG1 (1.6)
Abnormal MRI (n, %)28 (45.9)
With tumour (n, %)15 (24.6)
 Ovarian teratoma9 (14.8)
 Ovarian cysts5 (8.2)
 Colon carcinoma1 (1.6)
Symptoms of signs (n, %)
 Prodromal symptoms (fever, headache)28 (45.9)
 Psychiatric symptoms40 (65.6)
 Memory deficits9 (14.8)
 Speech disturbances21 (34.4)
 Seizures32 (52.3)
 Movement disorders24 (39.3)
 Loss of consciousness14 (23.0)
Treatment (n, %)
 First-line treatment33 (54.1)
 First-line combined with second-line treatment28 (45.9)
 Tumour removal12 (19.7)
With NICU support (n, %)24 (39.3)
  • *mRS was accessed 3 months after the treatment.

  • Abs, antibodies; BMI, body mass index; CMV, cytomegalovirus; CSF, cerebrospinal fluid; HSV, herpes simplex virus; NICU, neurological intensive care unit; anti-NMDAR, anti-N-Methyl-D-aspartate receptor; mRS, modified Rankin Scale.